Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives
ALK-directed immunotherapies represent promising approaches that may, if proven safe and effective in clinical trials, address resistance and improve long-term disease outcomes.
Despite advances in treatments, outcomes for many pediatric tumors remain limited, particularly in patients with high-risk, relapsed, or refractory disease.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Coexpression of MYCN and ALK Induces Neuroblastoma-Like Tumors From Human iPS Cell-Derived Cranial Neural Crest Cells.
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High‑Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study
- Treatment and Survival of Childhood Neuroblastoma: Evidence from a Population-Based Study in the United States
- Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study
- Research into neuroblastoma